Rebekah Barnes

Lupus Research Alliance Welcomes U.S. FDA Breakthrough Therapy Designation for Enpatoran for the Treatment of Lupus with Skin Manifestations

|

The Lupus Research Alliance welcomes the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation to enpatoran in clinical development by EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, for the treatment of lupus with active cutaneous manifestations. The FDA grants this designation to expedite the review of drugs for serious conditions that may demonstrate substantial improvement over available … Lupus Research Alliance Welcomes U.S. FDA Breakthrough Therapy Designation for Enpatoran for the Treatment of Lupus with Skin Manifestations

2026 LuCIN Community Meeting Focuses on Integrating Clinical Trials into Day-to-Day Clinical Care 

|

What if clinical trials were not a final option, but a routine part of lupus care?   That question took center stage at the 2026 Lupus Clinical Investigators Network (LuCIN) Community Meeting, where people living with lupus, researchers, clinicians, and industry leaders came together to reshape the future of treatment. LuCIN Investigators (left) and Coordinators join onsite for meaningful … 2026 LuCIN Community Meeting Focuses on Integrating Clinical Trials into Day-to-Day Clinical Care 

FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE

|

The U.S. Food and Drug Administration has accepted the supplemental Biologics License Application from Genentech for Gazyva® (obinutuzumab) to treat systemic lupus erythematosus (SLE), the most common form of lupus. The acceptance is based on Phase 3 data showing that Gazyva significantly reduced disease activity and less reliance on steroids in people with SLE.   According to results published in the New England Journal of Medicine and presented at SLEuro 2026, more than 75% of people treated with Gazyva plus standard therapy achieved … FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE

Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

|

Living with lupus means managing physical symptoms, emotional ups and downs, and the everyday challenges that come with an autoimmune condition. While there’s no one‑size‑fits‑all approach, many people find that caring for both the mind and body can make a meaningful difference.  To help support the lupus community, Lupus Therapeutics, the clinical affiliate of the Lupus … Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

Lupus Research Alliance Applauds U.S. FDA Fast Track Designation for Nipocalimab for Systemic Lupus Erythematosus 

|

Decision Could Help Potential SLE Treatment Reach People Living With Lupus Sooner The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Fast Track designation for nipocalimab in development by Johnson & Johnson for the treatment of adults with systemic lupus erythematosus (SLE) – a chronic autoimmune disease for which there are few treatment options. The FDA grants this designation “to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need” – with the goal of … Lupus Research Alliance Applauds U.S. FDA Fast Track Designation for Nipocalimab for Systemic Lupus Erythematosus 

Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus

|

The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen Inc. for the treatment of cutaneous lupus erythematosus (CLE) – a chronic skin disease for which there are no specifically approved treatments. The FDA grants this designation to expedite the review of drugs that may demonstrate substantial improvement over available therapies.   A common manifestation of lupus – a chronic and complex autoimmune disease – CLE primarily causes inflammation of the skin. Symptoms vary, but can include butterfly rashes, ring-shaped sores, or red, … Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus

Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

|

People living with lupus can have early access to innovative therapies alongside personalized support from a broader care team. How? Through participation in clinical trials.  Historically, clinical trial participation for lupus was discussed only after standard treatments failed the patient. Now, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, is working to make … Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

Lupus Clinical Research: A New Wave of Innovation 

|

A wave of lupus clinical research advances has been building over the past decade.  Now, it is reaching a crest.  A 2025 pipeline report identifies over 140 lupus therapies from 120+ companies now in clinical trials.i This surge of innovation is translating into potential treatments that are targeted, safer, and showing potential effectiveness for people living with lupus—offering more choices and options for treating the disease.  “This is … Lupus Clinical Research: A New Wave of Innovation 

Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative

|
Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative.

Imagine a future where everyday choices – like what people eat – could shape how lupus is treated and managed. That future may be closer than ever.   Earlier this year, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, launched a pioneering initiative: Investigate Dietary Approaches for Lupus (IDEAL). It is the first-ever program … Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative